In a report released on June 11, from UBS maintained a Hold rating on Giant Biogene Holding Co. Ltd., with a price target of HK$34.00. The company’s shares closed yesterday at HK$26.86.Introducing TipRanks MCP for Agents Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools. Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Giant Biogene Holding Co. Ltd. with a HK$40.06 average price target.
Based on Giant Biogene Holding Co. Ltd.’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of HK$2.41 billion and a net profit of HK$732.75 million. In comparison, last year the company earned a revenue of HK$3 billion and had a net profit of HK$1.08 billion
